IL15 and non-small cell lung carcinoma: IL-15 stimulation to ICI is likely safe, as demonstrated by a recent phase I clinical trial that established that IL-15 stimulation and PD-1 blockade are both safe and beneficial to a portion of NSCLC patients who had failed conventional therapies (61).